Multicentre open-label study of neurotransmitters and neuropeptides in schizophrenia: a multidisciplinary study of biological, pharmacokinetic, receptor occupancy and clinical relationships in patients suffering from schizophrenia treated with quetiapine (Seroquel).

Trial Profile

Multicentre open-label study of neurotransmitters and neuropeptides in schizophrenia: a multidisciplinary study of biological, pharmacokinetic, receptor occupancy and clinical relationships in patients suffering from schizophrenia treated with quetiapine (Seroquel).

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2012

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Schizophrenia
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 23 Jan 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top